PAXLOVID ORAL ( PFIZER ) . SE HA DEMOSTRADO QUE EL USO TEMPRANO DE NIRMATRELVIR / RITONAVIR ACORTA EL TIEMPO DE ELIMINACIÓN VIRAL EN PACIENTES INMUNOCOMPROMETIDOS Y HOSPITALIZADOS CON COVID19 .

 

Serplulimab Plus Chemotherapy As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer : A Cost-Effectiveness Analysis . SERPLULIMAB ( Henlius ) es el Potencial Nuevo Actor Para Tratamiento de Pacientes en Primera Línea .

 

Cáncer de Pulmón Microcítico . Análisis Sobre los Principales Actores , 2022 a 2030 , en la Investigación y Desarrollo del Mercado del Tratamiento del Cáncer de Pulmón de Células Pequeñas . Principales Actores Clave : Teva , Bristol Myers , Novartis , APP Pharmaceuticals , Elekta , Bedford .

Segmento de Mercado Por Regiones, Análisis Regional Cubre  : 

América del Norte (Estados Unidos, Canadá y México)
Europa (Alemania, Francia, Reino Unido, Rusia e Italia)
Asia-Pacífico (China, Japón, Corea, India y Sudeste Asiático)
América del Sur (Brasil, Argentina, Colombia, etc.)
Oriente Medio y África (Arabia Saudita, Emiratos Árabes Unidos, Egipto, Nigeria y Sudáfrica) . ...

Este informe estudia el mercado Tratamiento del cáncer de pulmón de células pequeñas con muchos aspectos de la industria, como el tamaño del mercado, el estado del mercado, las tendencias del mercado y el pronóstico, el informe también proporciona información breve sobre los competidores y las oportunidades de crecimiento específicas con los impulsores clave del mercado. Encuentre el análisis completo del mercado Tratamiento del cáncer de pulmón de células pequeñas segmentado por compañías, regiones, tipos y aplicaciones en el informe.

El informe ofrece información valiosa sobre el progreso del mercado Tratamiento del cáncer de pulmón de células pequeñas y enfoques relacionados con el mercado Tratamiento del cáncer de pulmón de células pequeñas con un análisis de cada región. El informe continúa hablando sobre los aspectos dominantes del mercado y examina cada segmento. ...

LONG COVID , POTENCIAL NUEVO TRATAMIENTO DESDE JAPÓN . La Terapia Abrasiva Epifaríngea Puede Ser Eficaz Para Mejorar los Síntomas del Tracto Respiratorio Superior en Pacientes con COVID PROLONGADO .

A Potential Novel Treatment for Chronic Cough in Long COVID Patients: Clearance of Epipharyngeal Residual SARS-CoV-2 Spike RNA by Epipharyngeal Abrasive Therapy .

A major target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the epipharyngeal mucosa .

Epipharyngeal abrasive therapy (EAT) is a Japanese treatment for chronic epipharyngitis .

EAT is a treatment for chronic epipharyngitis in Japan that involves applying zinc chloride as an anti-inflammatory agent to the epipharyngeal mucosa. Here, we present a case of a 21-year-old man with chronic coughing that persisted for four months after a diagnosis of mild coronavirus disease 2019 (COVID-19), who was treated by EAT .

We diagnosed chronic epipharyngitis as the cause of the chronic cough after the SARS-CoV-2 infection. SARS-CoV-2 spike RNA had persisted in the epipharyngeal mucosa of this Long COVID patient .

 EAT was performed once a week for three months, which eliminated residual SARS-CoV-2 RNA and reduced epipharyngeal inflammation .

 Moreover, a reduction in the expression of proinflammatory cytokines was found by histopathological examination .

We speculate that the virus was excreted with the drainage induced by EAT, which stopped the secretion of proinflammatory cytokines .

This case study suggests that EAT is a useful treatment for chronic epipharyngitis involving long COVID . ...

IAG REMONTA EL VUELO . Y Ya Re­cu­pera Prác­ti­ca­mente Toda la Red de Des­tinos y su Ca­pa­cidad Previa a 2020 con una Ocu­pa­ción Que Ron­dará el 90 % . ¡ ESTAMOS ANTE UNA IMPORTANTE RECUPERACIÓN DE LOS INGRESOS Y EL ADIÓS A LA CRISIS ! .

 

Small Cell Lung Cancer . Tempus / AstraZeneca Anuncian un Estudio Prospectivo Para el Descubrimiento de Biomarcadores en el Cáncer de Pulmón de Células Pequeñas .

 

AstraZeneca and Tempus Announces Prospective Study For Biomarker Discovery in Small Cell Lung Cancer .

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca’s Personalize SCLC Initiative and is currently open for enrollment.

In the United States, lung cancer is the second most common cancer, and approximately 13% of people diagnosed with lung cancer have SCLC, according to the American Cancer Society. SCLC is an aggressive disease characterized by rapid growth, early metastasis, and acquired therapeutic resistance in which there is a high unmet need for therapeutic targets. To date, there are limited ways to stratify this specific patient population and limited defined therapeutic targets or associated treatments.

The Sculptor study is leveraging Tempus’ comprehensive portfolio of molecular profiling offerings to gather the insights necessary to support this kind of early research, with the goal of identifying distinct segments that may benefit from emerging therapies, or a treatable target from which to develop an associated therapy to treat patients with SCLC. This study is currently active at five TIME Trial Network sites, with plans to expand to additional providers across the country to ensure the study’s dataset is representative of the overall SCLC patient population in the United States.

“This collaborative study will facilitate the investigation of SCLC patient populations to provide us with key insights in hopes of enabling pharmaceutical solutions that increase the overall survival of this disease,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “This type of early-stage, prospective study is only possible when combining Tempus’ comprehensive sequencing capabilities, multimodal database, and just-in-time clinical trial network.” 

JazzPharma . Statement of Changes In Beneficial Ownership Of Securities By COZADD BRUCE C . Chairman / CEO / Co-Founder , Jazz Pharmaceuticals PLC .